The’IMCIVREE (setmélanotide) is different from all other weight management treatments: it is not intended for the general population, but is approved by Health Canada for specific genetic markers and rare, associated with a specific disruption of the weight-regulating pathway known as the MC4R pathway.
On this page
- What is IMCIVREE (setmelanotide)?
- Understanding the MC4R pathway and its role
- Who is eligible to apply to IMCIVREE?
- Why This Is Not a Treatment for General Obesity
- Protocol for Administration and Medical Monitoring
- Side Effects and Precautions
- Access to IMCIVREE in Quebec
- Myths and misconceptions
- Frequently asked questions
What is IMCIVREE (setmelanotide)?
Visit setmelanotide is an agonist of the MC4R (melanocortin-4 receptor), a pharmacological target that is very different from that of GLP-1 agonists or other weight management options. IMCIVREE is approved by Health Canada for the management of chronic weight in patients with certain confirmed genetic variants affecting the MC4R signaling pathway.
This treatment is intended for a very specific group of patients—those diagnosed through genetic testing—and not for anyone seeking pharmacological assistance with weight management.
To remember
- IMCIVREE contains setmelanotide, an MC4R receptor agonist
- Weekly subcutaneous injection
- Approved by Health Canada for specific genetic indications, not for general obesity
- Requires genetic confirmation prior to treatment
- Typically prescribed and monitored in collaboration with a specialized center
- Always prescribed as a supplement to multidisciplinary care
Understanding the MC4R pathway and its role
The MC4R pathway is an appetite-regulating circuit located in the hypothalamus. In some people, a genetic variant affecting specific genes in this pathway (for example, those associated with syndromes such as POMC deficiency, LEPR deficiency, or Bardet-Biedl syndrome) disrupts this mechanism and leads to severe weight gain beginning in childhood, despite standard interventions.
What Setmélanotide Does
- Reactivates MC4R receptor signaling in patients with certain variants
- Aims to reduce the excessive appetite associated with these specific genetic conditions
- Has not been shown to be equally effective in people without confirmed involvement of this pathway
Who is eligible to apply to IMCIVREE?
Eligibility for IMCIVREE is strictly regulated:
| Criteria | Requirement |
|---|---|
| Genetic confirmation | A specific variant of the MC4R gene that has been documented |
| Age | According to the approved specific instructions |
| Specialized assessment | Typically in collaboration with a specialized center |
A genetic test confirming a specific defect in the MC4R pathway is an essential prerequisite—IMCIVREE is not prescribed based solely on a high body mass index.
Why This Is Not a Treatment for General Obesity
- Treatments such as Saxenda and Wegovy are intended for a broader population, based on BMI criteria
- IMCIVREE targets a specific, well-documented genetic cause, not simply excess weight
- The diagnosis is based on a genetic test, not just on a clinical examination
This distinction is essential: a patient without genetic confirmation of the MC4R pathway will generally not be referred for this treatment, regardless of the severity of their weight-related condition.
Protocol for Administration and Medical Monitoring
Stepwise titration
Treatment begins at a low dose, which is gradually adjusted based on tolerance and clinical response, under specialized medical supervision.
Clinical follow-up required
- Genetic confirmation prior to starting treatment
- Periodic follow-up at a specialized center, in collaboration with the primary care physician
- Regular assessment of weight response and tolerability
- Skin monitoring (pigmentation) related to the mechanism of action
Side Effects and Precautions
Reported side effects include injection-site reactions, nausea, and changes in skin pigmentation related to the drug’s mechanism of action on melanocortin receptors. Dermatological follow-up may be recommended depending on the patient’s profile. Only a healthcare professional—typically at a specialized center—can determine whether this treatment is appropriate based on a patient’s complete medical and genetic history.
Access to IMCIVREE in Quebec
Admission to the IMCIVREE requires a thorough medical evaluation, including a referral for genetic testing and, generally, collaboration with a center specializing in metabolic genetics or endocrinology. Our service locations in Quebec can guide patients through this diagnostic process and provide follow-up care in collaboration with the relevant specialists.
A comprehensive medical evaluation is the first step in determining whether a referral to IMCIVREE is appropriate in your situation. Make an appointment at one of our service locations in Quebec, or choose a online consultation. Companies interested in a wellness program for their employees can review our offerings for companies.
Myths and misconceptions
«IMCIVREE is an option for anyone who is overweight»
False. IMCIVREE is indicated only for specific, confirmed genetic conditions, not for general obesity.
«A genetic test isn't really necessary.»
False. Genetic confirmation of a defect in the MC4R pathway is an essential prerequisite before considering this treatment.
«It's more effective than other weight-management treatments.»
Nuanced. IMCIVREE is not «more potent»; it targets a different mechanism and is effective only in patients whose genetic cause corresponds to its mechanism of action.
«Genetic testing is time-consuming and inaccessible.»
Nuanced. Access to genetic testing and specialized evaluation varies depending on the situation, but an initial medical evaluation helps determine the appropriate next steps.
«The treatment is permanent.»
Nuanced. The duration of treatment is determined in consultation with the specialized medical team based on the clinical response and the established goals.
Frequently asked questions
Is IMCIVREE covered by RAMQ?
Coverage varies depending on the insurance plan, the specific medical condition, and the eligibility criteria. It is recommended that you check your specific coverage with your insurer or the RAMQ.
Who should consider genetic testing for the MC4R pathway?
This decision is made by the attending physician, typically in cases of severe, early-onset weight gain that cannot be explained by the usual causes. A comprehensive medical evaluation helps guide this process.
How long before I see results?
The timeframe varies depending on the specific genetic condition and the individual’s response. Specialized medical follow-up allows for an assessment of the condition’s progression and adjustments to the treatment plan.
Is IMCIVREE suitable for children?
The specific indication and age of eligibility depend on Health Canada’s approval and must be confirmed with a specialist, typically at a center specializing in metabolic genetics or pediatric endocrinology.
What is the difference between IMCIREE and other weight management treatments?
IMCIVREE targets a specific genetic cause related to the MC4R pathway, whereas the other options (Saxenda, Wegovy, Contrave, Xenical) are intended for a broader population based on BMI criteria. The choice depends on an individualized medical and genetic evaluation.
Sources
- Health Canada — Pharmaceutical Products Database
- National Institute for Excellence in Health and Social Services (INESSS)
- Quebec Ministry of Health and Social Services (MSSS)
- Quebec College of Physicians (CMQ) — Guidelines on Weight Management
- Quebec Health Insurance Board (RAMQ)
Recommended Reading
- Saxenda in Quebec: Liraglutide for Weight Management
- Contrave in Quebec: naltrexone/bupropion tablets
- Xenical in Quebec: Orlistat and Fat Digestion
- World Obesity Day: Medical Care in Quebec
- Understanding the Rare Genetic Causes of Early-Onset Severe Obesity
This information is provided for educational purposes only and is not a substitute for the advice of a healthcare professional. Consult a doctor if you have any questions about your health.
Omicron Clinic
Need to consult a doctor?
In-person or via telemedicine, anywhere in Quebec.
We accept insurance. Telemedicine consultations available 7 days a week. No family doctor required.
